Answer

What does a GLP-1 do besides weight loss?

GLP-1 Agonists glp-1 cardiovascular addiction longevity

By Arun AgrahriLast reviewed

Short answer

Fewer heart attacks and strokes, possibly apart from weight loss, but there is too little counted evidence to be sure. The one counted source, a semaglutide trial as described on tape, saw much of that gap open before people had lost much weight. Precis has not read the trial itself.

Best for:
people on a GLP-1, or thinking of one, who want to know what else it does.
Price:
Free to read, with every receipt. Pro is $9 a month or $79 a year and adds AI Ask.
Based on what researchers say in public interviews on YouTube. Educational only, not medical advice. Ask a qualified clinician before changing a supplement, medication, treatment, or testing plan.
Leaning for

GLP-1 drugs are worth taking for people with obesity.

The verdict on GLP-1 Agonists overall. 18 sources: 6 positive, 9 partly, 3 negative

What the evidence says

positive partly neutral negative Each researcher and each study counts once per claim, however often they come up.

  1. Not enough evidence

    GLP-1 drugs cut cardiovascular events partly independent of weight loss.

    2 sources: 2 positive. Fewer than 3 sources so far.

    Researchers say

    No researcher counted yet.

    Studies show

    2 positive

    1 paper we read · 1 cited on tape, not yet checked against the paper

    23 more not counted · see why
    Show the receipts from 2 sources
    1. SELECT, cited on Huberman Lab, at 1:28:22 Study · positive

      “was really surprising was a lot of that seemed to happen before the people even lose weight lost weight”

    2. Controlled trial, N Engl J Med, 2023, PMID 37952131 Study · positive

      However, the data are consistent with the between-group difference in the incidence of cardiovascular disease emerging early in this trial, which suggests that more rapid treatment-induced physiological changes beyond the magnitude of body-weight loss may have mediated at least part of the cardiovascular benefit.

Precis is not affiliated with or endorsed by YouTube or by any researcher, show or publisher we quote. We take no sponsorship, ad or affiliate money, and every verdict is our own review of what was said. How we stay independent

Detailed Answer

The only counted source here is a large semaglutide trial, as Zachary Knight describes it as a guest on Andrew Huberman's show. Precis has not read the trial itself, so this rests on his account. Four other mentions sit on the claim without being counted, because their origin or stance was unclear.

The heart

Knight says the trial cut heart attacks, strokes and deaths from heart causes, as expected. The surprise was the timing. The drug and placebo groups already differed before the people on the drug had lost much weight.

He adds that how much weight people lost did not track how well they were protected. One idea he describes is that the drugs calm inflammation through the inflammatory reflex, a loop that runs from the vagus nerve to the brainstem and back to the body. He presents that as an idea that is still emerging.

Cravings and alcohol

Anna Lembke, a guest on Peter Attia's show, describes rarely giving semaglutide off label to patients whose alcohol use disorder had resisted everything else. In one patient, she says, alcohol craving stopped completely. That is one case, and it is not counted here.

Risks raised on tape

Ben Bikman, a guest on Rhonda Patrick's show, cites a newly published paper linking high-dose GLP-1 use to a higher risk of blindness. He stresses that the link is correlational and that he cannot say the drug causes it. He also cites data in which people on the higher weight-loss dose had more diagnosed major depression and suicidal behavior.

Mark Hyman, on his own show, argues against taking a GLP-1 for longevity. Among the side effects that concern him he lists gastroparesis (a stomach that stops emptying), bowel obstruction and pancreatitis, and he warns that much of the weight lost is muscle. He also says he is not against the drug for the right patient.

Neither Bikman's nor Hyman's remarks are counted toward this claim.

What no counted source shows

No counted source shows that a GLP-1 slows aging itself. If you take one or are weighing it, go over these risks with your prescriber.

Related Questions

Do GLP-1s help the heart?
The one counted source, a semaglutide trial as Knight describes it, saw fewer heart attacks and strokes, much of it before people lost much weight. One source is too few to settle whether the benefit holds apart from weight loss.
Can GLP-1s help with alcohol or addiction?
Lembke describes one patient with hard-to-treat alcohol use disorder whose craving stopped on semaglutide, given off label. That is a single case and is not counted toward this claim.
Do GLP-1s slow aging?
No counted source shows that. Hyman argues against taking a GLP-1 for longevity, and Bikman raises blindness and depression signals at higher doses. Neither remark is counted toward this claim.

More Questions About GLP-1 Agonists

Precis membership

Get the exact protocol for GLP-1 Agonists

The answer above is the whole answer: the verdict, every counted mention, where the sources disagree, and the receipt behind each one. Nothing on this page is held back.

A free account adds

  • Each dose named on the record, and the form named with it
  • Timing, and what to take it with or keep it away from
  • The interactions flagged by name

Pro adds

  • Chat answers drawn from 3,800+ hours of recorded interviews with 380+ researchers and doctors, plus 87,700+ research studies, each with a timecode
Go Pro — $9/mo or $79/yr

Full GLP-1 Agonists evidence report

The verdict on every claim, and where the sources disagree

How Precis checks a claim · Report an error